1. Home
  2. GRPN vs VTYX Comparison

GRPN vs VTYX Comparison

Compare GRPN & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Groupon Inc.

GRPN

Groupon Inc.

HOLD

Current Price

$16.27

Market Cap

723.4M

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$13.73

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRPN
VTYX
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
723.4M
713.6M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
GRPN
VTYX
Price
$16.27
$13.73
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$31.25
$14.60
AVG Volume (30 Days)
980.2K
1.4M
Earning Date
11-06-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$496,093,000.00
N/A
Revenue This Year
$4.17
N/A
Revenue Next Year
$10.63
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.21
$0.78
52 Week High
$43.08
$25.00

Technical Indicators

Market Signals
Indicator
GRPN
VTYX
Relative Strength Index (RSI) 40.49 75.47
Support Level $17.43 $7.08
Resistance Level $17.93 $9.30
Average True Range (ATR) 0.71 0.74
MACD -0.01 0.25
Stochastic Oscillator 15.72 80.63

Price Performance

Historical Comparison
GRPN
VTYX

About GRPN Groupon Inc.

Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: